Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  Includes (i) 568,234 shares of common stock, $0.0001 par value per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 77,371 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 81,876 shares of Common Stock held by other separately managed accounts as of March 31, 2026. Excludes 1,230,315 shares of Common Stock underlying common warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 4.99% beneficial ownership limitations. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts. Based on 9,393,514 shares of Common Stock of LeonaBio, Inc. (the "Issuer") outstanding as of March 31, 2026, reported in the Issuer's Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on May 7, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  Includes (i) 568,234 shares of common stock, $0.0001 par value per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 77,371 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 81,876 shares of Common Stock held by other separately managed accounts as of March 31, 2026. Excludes 1,230,315 shares of Common Stock underlying common warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 4.99% beneficial ownership limitations. As the manager of ADAR1 Capital Management, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above. Based on 9,393,514 shares of Common Stock of LeonaBio, Inc. (the "Issuer") outstanding as of March 31, 2026, reported in the Issuer's Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on May 7, 2026.


SCHEDULE 13G



 
ADAR1 Capital Management, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:05/15/2026
 
Daniel Schneeberger
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:05/15/2026
Exhibit Information

Exhibit A: Joint Filing Agreement

 

EXHIBIT A

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to shares of Common Stock, $0.0001 par value per share, of LeonaBio Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.

 

In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of May 15, 2026.

 

  ADAR1 CAPITAL MANAGEMENT, LLC
   
  /s/ Daniel Schneeberger
  Daniel Schneeberger
  Manager
    
  /s/ Daniel Schneeberger
  Daniel Schneeberger, in his individual capacity